These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 35836330)

  • 21. Establishment of an AUC
    Chavada R; Ghosh N; Sandaradura I; Maley M; Van Hal SJ
    Antimicrob Agents Chemother; 2017 May; 61(5):. PubMed ID: 28242672
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Retrospective review of vancomycin monitoring via trough only versus two-point estimated area under the curve in pediatric and adult patients with cystic fibrosis.
    Mitchell B; Kormelink L; Kuhn R; Schadler A; Autry E
    Pediatr Pulmonol; 2023 Jan; 58(1):239-245. PubMed ID: 36203329
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Eradication of methicillin resistant Staphylococcus aureus detected for the first time in cystic fibrosis: A single center observational study.
    Kappler M; Nagel F; Feilcke M; Kröner C; Pawlita I; Naehrig S; Ripper J; Hengst M; von Both U; Forstner M; Hector A; Griese M
    Pediatr Pulmonol; 2016 Oct; 51(10):1010-1019. PubMed ID: 27378061
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Outcomes and Treatment of Chronic Methicillin-Resistant Staphylococcus aureus Differs by Staphylococcal Cassette Chromosome mec (SCCmec) Type in Children With Cystic Fibrosis.
    Heltshe SL; Saiman L; Popowitch EB; Miller MB; Kloster M; Thompson V; Ferkol TW; Hoover WC; Schechter MS; Muhlebach MS
    J Pediatric Infect Dis Soc; 2015 Sep; 4(3):225-31. PubMed ID: 26336603
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Emperor's New Clothes: PRospective Observational Evaluation of the Association Between Initial VancomycIn Exposure and Failure Rates Among ADult HospitalizEd Patients With Methicillin-resistant Staphylococcus aureus Bloodstream Infections (PROVIDE).
    Lodise TP; Rosenkranz SL; Finnemeyer M; Evans S; Sims M; Zervos MJ; Creech CB; Patel PC; Keefer M; Riska P; Silveira FP; Scheetz M; Wunderink RG; Rodriguez M; Schrank J; Bleasdale SC; Schultz S; Barron M; Stapleton A; Wray D; Chambers H; Fowler VG; Holland TL
    Clin Infect Dis; 2020 Apr; 70(8):1536-1545. PubMed ID: 31157370
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Interventions for the eradication of meticillin-resistant Staphylococcus aureus (MRSA) in people with cystic fibrosis.
    Lo DK; Muhlebach MS; Smyth AR
    Cochrane Database Syst Rev; 2018 Jul; 7(7):CD009650. PubMed ID: 30030966
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacokinetic/Pharmacodynamic Target Attainment of Vancomycin, at Three Reported Infusion Modes, for Methicillin-Resistant
    Song X; Han M
    Front Cell Infect Microbiol; 2022; 12():874401. PubMed ID: 35873144
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of Vancomycin or Daptomycin With vs Without an Antistaphylococcal β-Lactam on Mortality, Bacteremia, Relapse, or Treatment Failure in Patients With MRSA Bacteremia: A Randomized Clinical Trial.
    Tong SYC; Lye DC; Yahav D; Sud A; Robinson JO; Nelson J; Archuleta S; Roberts MA; Cass A; Paterson DL; Foo H; Paul M; Guy SD; Tramontana AR; Walls GB; McBride S; Bak N; Ghosh N; Rogers BA; Ralph AP; Davies J; Ferguson PE; Dotel R; McKew GL; Gray TJ; Holmes NE; Smith S; Warner MS; Kalimuddin S; Young BE; Runnegar N; Andresen DN; Anagnostou NA; Johnson SA; Chatfield MD; Cheng AC; Fowler VG; Howden BP; Meagher N; Price DJ; van Hal SJ; O'Sullivan MVN; Davis JS;
    JAMA; 2020 Feb; 323(6):527-537. PubMed ID: 32044943
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Vancomycin area under the curves estimated with pharmacokinetic equations using trough-only data.
    Fewel N
    J Clin Pharm Ther; 2021 Oct; 46(5):1426-1432. PubMed ID: 34169543
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Population Pharmacokinetics and Safety of Ceftolozane-Tazobactam in Adult Cystic Fibrosis Patients Admitted with Acute Pulmonary Exacerbation.
    Monogue ML; Pettit RS; Muhlebach M; Cies JJ; Nicolau DP; Kuti JL
    Antimicrob Agents Chemother; 2016 Nov; 60(11):6578-6584. PubMed ID: 27550351
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Development and Preclinical Evaluation of New Inhaled Lipoglycopeptides for the Treatment of Persistent Pulmonary Methicillin-Resistant Staphylococcus aureus Infections.
    Plaunt AJ; Rose SJ; Kang JY; Chen KJ; LaSala D; Heckler RP; Dorfman A; Smith BT; Chun D; Viramontes V; Macaluso A; Li Z; Zhou Y; Mark L; Basso J; Leifer FG; Corboz MR; Chapman RW; Cipolla D; Perkins WR; Malinin VS; Konicek DM
    Antimicrob Agents Chemother; 2021 Jun; 65(7):e0031621. PubMed ID: 33941518
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Successful treatment of methicillin-resistant Staphylococcus aureus pulmonary infection with linezolid in a patient with cystic fibrosis.
    Ferrin M; Zuckerman JB; Meagher A; Blumberg EA
    Pediatr Pulmonol; 2002 Mar; 33(3):221-3. PubMed ID: 11836802
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparative Effectiveness of Vancomycin Versus Daptomycin for MRSA Bacteremia With Vancomycin MIC >1 mg/L: A Multicenter Evaluation.
    Moise PA; Culshaw DL; Wong-Beringer A; Bensman J; Lamp KC; Smith WJ; Bauer K; Goff DA; Adamson R; Leuthner K; Virata MD; McKinnell JA; Chaudhry SB; Eskandarian R; Lodise T; Reyes K; Zervos MJ
    Clin Ther; 2016 Jan; 38(1):16-30. PubMed ID: 26585355
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Use of telavancin in adolescent patients with cystic fibrosis and prior intolerance to vancomycin: A case series.
    Bernstein AT; Leigh MW; Goralski JL; Esther CR; McKinzie CJ
    J Cyst Fibros; 2018 Nov; 17(6):e48-e50. PubMed ID: 30170755
    [TBL] [Abstract][Full Text] [Related]  

  • 35. First-Dose Vancomycin Pharmacokinetics Versus Empiric Dosing on Area-Under-the-Curve Target Attainment in Critically Ill Patients.
    Flannery AH; Delozier NL; Effoe SA; Wallace KL; Cook AM; Burgess DS
    Pharmacotherapy; 2020 Dec; 40(12):1210-1218. PubMed ID: 33176005
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Successful eradication of newly acquired MRSA in six of seven patients with cystic fibrosis applying a short-term local and systemic antibiotic scheme.
    Kiefer A; Bogdan C; Melichar VO
    BMC Pulm Med; 2018 Jan; 18(1):20. PubMed ID: 29370836
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacokinetics of vancomycin in adult cystic fibrosis patients.
    Pleasants RA; Michalets EL; Williams DM; Samuelson WM; Rehm JR; Knowles MR
    Antimicrob Agents Chemother; 1996 Jan; 40(1):186-90. PubMed ID: 8787903
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Methicillin-resistant Staphylococcus aureus in children with cystic fibrosis: An eradication protocol.
    Solís A; Brown D; Hughes J; Van Saene HK; Heaf DP
    Pediatr Pulmonol; 2003 Sep; 36(3):189-95. PubMed ID: 12910579
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Aerosolized vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infection in cystic fibrosis.
    Máiz L; Cantón R; Mir N; Baquero F; Escobar H
    Pediatr Pulmonol; 1998 Oct; 26(4):287-9. PubMed ID: 9811080
    [No Abstract]   [Full Text] [Related]  

  • 40. Comparison of continuous infusion versus intermittent infusion of vancomycin in patients with methicillin-resistant Staphylococcus aureus.
    Jaruratanasirikul S; Julamanee J; Sudsai T; Saengsuwan P; Jullangkoon M; Ingviya N; Jarumanokul R
    J Med Assoc Thai; 2010 Feb; 93(2):172-6. PubMed ID: 20301996
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.